As modern medicine began in the 20th century, most of the early research efforts were focused on developing and refining treatment modalities. This focus on therapeutic efficacy was rightly so, as a profession cannot begin to exist and flourish until an armamentarium of tools is available for its practitioners. The randomized control trial (RCT) emerged during this time as the gold standard for clinical research, given its unparalleled strength in isolating therapeutic effects and confirming the efficacy of new treatment modalities.
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However, toward the end of the 20th century, there was a growing recognition that health outcomes are not reducible to therapy alone. With documentation of the wide variation in patient treatment and outcomes worldwide, health care providers and researchers began to appreciate that health outcomes result from the complex interaction of 3 main factors: 1, 2 Outcome ¼ therapeutic þ patient þ provider Within our complex and ever-evolving systems of health care, outcomes research, more formally known as health services research (HSR), emerged as a new research tool. Although the traditional RCT focuses primarily on the therapeutic factor in the above-mentioned framework by neutralizing the impact of patients and providers, HSR examines therapeutic efficacy in ''real-world'' settings where care takes place and focuses on those human aspects (patient and provider factors) that are difficult for RCTs to evaluate. In other words, HSR exists not to replace the RCT but to complement RCTs by filling important knowledge gaps about patient outcomes that are difficult to examine with RCT methodology.
More specifically, HSR is uniquely positioned to examine 3 major topical areas: (1) how patient factors affect outcomes, (2) how provider factors affect outcomes, and (3) which patient populations will benefit from a given therapy.
Health services research informs us about patient
factors and their impact on disease outcomes. Patient factors include age, weight, sex, race, socioeconomic status, comorbid disease, and insurance status. A common assumption of RCTs is that most diseases follow a natural biological history and display an objective biological response to therapeutics. However, in practice, an individual's experience with a disease is contextualized by social and biological factors that alter both the disease course and the response to therapeutics. For example, the Open Versus Endovascular Repair (OVER) trial randomized patients to receive endovascular (EVAR) versus open repair (OAR) of abdominal aortic aneurysms (AAAs) and found that fewer deaths resulted from endovascular repair. 3 However, the study did not analyze how patient factors might have played a role in mortality while comparing these 2 procedures.
In this case, we do not know how a patient's race, gender, or comorbidities affect mortality because results were only presented in the context of patients who were treated or untreated. In contrast, Ramanan et al utilized the National Surgical Quality Improvement Program (NSQIP) database to create a risk index to predict mortality following open AAA repair. They included patient factors such as dyspnea, previous peripheral revascularization or amputation, age >65 years old, creatinine >1.5 mg/dL, platelets <150 000 or >350.000/mm3, and sex to determine patients' risk before open AAA repair. 4 Each of these patient factors were uniquely associated with increased mortality following surgery and may affect surgical decision making.
2. Health services research informs us about provider effects and their impact on treatment and disease outcomes. Provider effects include the impact of the system as a whole including nurses, physicians, regional factors, administrative variability, and hospital characteristics such as volume, teaching status, or physician experience. In traditional RCTs examining the impact of a pharmaceutical agent, provider factors are typically overlooked because providers are blinded, and the individual prescribing the drug does not affect how well the drug works. However, in surgery there is substantial evidence documenting significant variability in outcomes based on the individual (or team) providing care. Returning to the example of the OVER trial, this study recruited patients solely at Veterans Affairs (VA) Hospitals and reflects the care provided by that specific health care system and no others. 3 Equally, because the trial enrolled patients through the VA hospital system, there is little understanding of how screening and follow-up protocols might vary in privately insured patients or the uninsured. Alternatively, the Ramanan study utilized data from the NSQIP database and thus had patient data from 183 hospitals in 2007, 211 in 2008, and 237 in 2009. 4 The hospitals that report to NSQIP include academic and community centers and thus a variety of types of providers are included. Additionally, the OVER trial did not take into account the effect of hospital variability within the VA system such as case volume or teaching status in determining the mortality rate of endovascular and open AAA repair. 3 Birkmeyer et al showed that the 30-day mortality for elective repair of AAA among Medicare patients drops from 6.5% to 3.9% when comparing very low-volume to very high-volume centers. 5 This difference remained significant after adjusting for patient characteristics. Furthermore, the OVER trial did not consider that in many US hospitals, EVARs are frequently performed by interventionalists and not vascular surgeons, which has been shown to increase cost, length of stay, and mortality in reviews of the Nationwide Inpatient Sample. 6 
Health services research informs us about proper indi-
cations and differences in therapeutic benefits across populations. The RCTs typically have strict inclusion criteria in order to recruit a homogenous set of patients. For that reason, these patients may differ significantly from other patients who will receive the same treatment outside the study. This ultimately calls the study's generalizability into question since the study population did not accurately reflect the future patient population. It is therefore difficult to discern the true indication of a therapeutic from homogenous RCT cohorts. Some patients may benefit more than others, but a standard RCT will overlook this trend because RCTs typically do not enroll enough patients for subset analysis. For example, if one is interested in determining whether men and women would benefit equally from a therapeutic intervention, and the study requires 500 patients in each comparison group to detect a clinically meaningful difference in a particular outcome, then its sample size requirement would double to 1000, requiring 500 men to be randomized and another 500 women randomized. The sample size requirement would further escalate exponentially for every other patient category that one would wish to test (eg, for every racial group, age groups, etc), which would make the study impractical to execute. This problem is further reflected in a recent call for more research into ''appropriateness criteria.'' 7 For example, the OVER trial included patients with an average age of 70 with a standard deviation of 7.8 years. 3 This means there was only a small percentage of patients below the age of 60. This sample size was not large enough to draw any conclusion about whether AAA repair would benefit patients below the age of 60. In contrast, Schwarze et al utilized the Nationwide Inpatient Sample to analyze outcomes after EVAR or OAR in patients aged 50 to 64, 65 to 74, 75 to 84, and greater than 85. 8 The study demonstrated that the adjusted length of stay was less for each age group who had elective EVAR instead of OAR, with the oldest patients receiving the most benefit. Here, HSR informs practitioners that EVAR may be appropriate for younger patients as well as the elderly.
This expanded understanding of patient outcomes is further illustrated by a consensus statement of members of the Society of Vascular Surgery regarding research priorities. 9 A total of 53 research topics were discussed until ultimately 9 were deemed most important. Of the top 9 topics, 3 were related to proper indications of a treatment regimen (eg, compare effectiveness of initial open vs endovascular infrainguinal revascularization for critical limb ischemia), and another 3 were related to higher level systems issues (eg, to identify and eliminate barriers to vascular surgeons working collaboratively with PCP and cardiologists to modify atherosclerotic risk factors). 9 Additionally, some of the original list of 53 topics were related to patient factors (eg, to define clinical and anatomic characteristics in patients with asymptomatic carotid stenosis that place them at high risk of stroke). 9 The examples here demonstrate how HSR fills the knowledge gap left by the RCT framework and can contribute to current research priorities. Outcomes databases already include much of the necessary information to conduct research on patient and provider factors. For example, to assess the impact of patient factors on outcomes, one can look to the multivariate analysis and determine the effect of age, race, gender, and insurance status on outcomes. To determine whether provider factors affect outcomes, one can include hospital or regional variables in the multivariate analysis and demonstrate how they impact outcomes in addition to the patient factors described previously. To determine which patient will benefit from a therapeutic regimen, one can look to subset analyses, repeating the same multivariate analysis in different subpopulations to determine whether the therapeutic effect still exists. A good example of an outcomes database for vascular surgery where many of these questions are being answered is the Vascular Quality Initiative. 10 In conclusion, as we march into the second century of modern medicine, we need to expand the research agenda to include more than therapeutics alone. We need research methodologies that address the complexities of our health care systems, the diversity of patients in the modern world, and how the 2 interact to affect patient outcomes. The utility of the RCTs to answer questions regarding safety and efficacy of a specific therapy remains undisputed. However, HSR is essential to expand our understanding of how other human factors can affect patient outcomes. The combination of RCTs and HSR is essential for us to continue to enhance patient outcomes in the 21st century.
